Imaging Response to Contemporary Immuno-oncology Combination Therapies in Patients With Metastatic Renal Cell Carcinoma-Reference-Cited by-同舟云学术

Imaging Response to Contemporary Immuno-oncology Combination Therapies in Patients With Metastatic Renal Cell Carcinoma

Published:2022-06-10 Issue:6 Volume:5 Page:e2216379
ISSN:2574-3805
Container-title:JAMA Network Open
language:en
Short-container-title:JAMA Netw Open

Author:

Navani Vishal¹,Ernst Matthew¹,Wells J. Connor²,Yuasa Takeshi³,Takemura Kosuke³,Donskov Frede⁴,Basappa Naveen S.⁵,Schmidt Andrew⁶,Pal Sumanta K.⁷,Meza Luis⁷,Wood Lori A.⁸,Ernst D. Scott⁹,Szabados Bernadett¹⁰,Powles Thomas¹⁰,McKay Rana R.¹¹,Weickhardt Andrew¹²,Suarez Cristina¹³,Kapoor Anil¹⁴,Lee Jae Lyun¹⁵,Choueiri Toni K.⁶,Heng Daniel Y. C.¹

Affiliation:

1. Tom Baker Cancer Centre, Department of Medical Oncology, University of Calgary, Calgary, Canada

2. BC Cancer Agency, Vancouver, Canada

3. Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan

4. Department of Oncology, Aarhus University Hospital, Aarhus, Denmark

5. Cross Cancer Institute, Department of Medical Oncology, University of Alberta, Edmonton, Canada

6. Dana Farber Cancer Institute, Boston, Massachusetts

7. City of Hope Comprehensive Cancer Center, Duarte, California

8. Queen Elizabeth II Health Sciences Centre, Halifax, Canada

9. London Regional Cancer Centre, London, Canada

10. Barts Cancer Institute, Queen Mary University of London, London, United Kingdom

11. Moores Cancer Center, University of California, San Diego, La Jolla

12. Olivia Newton-John Cancer and Wellness Centre, Melbourne, Australia

13. Vall d’Hebron Institute of Oncology, Universitat Autònoma de Barcelona, Barcelona, Spain

14. Juravinski Cancer Centre, McMaster University, Hamilton, Canada

15. University of Ulsan College of Medicine, Asan Medical Center, Seoul, Republic of Korea

Publisher

American Medical Association (AMA)

Subject

General Medicine

Link

https://jamanetwork.com/journals/jamanetworkopen/articlepdf/2793226/navani_2022_oi_220480_1654263489.7591.pdf

Reference37 articles.

1. Treatment selection in first-line metastatic renal cell carcinoma—the contemporary treatment paradigm in the age of combination therapy: a review.;Navani;JAMA Oncol,2022

2. Defining tumor resistance to PD-1 pathway blockade: recommendations from the first meeting of the SITC Immunotherapy Resistance Taskforce.;Kluger;J Immunother Cancer,2020

3. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).;Eisenhauer;Eur J Cancer,2009

4. Evaluation of overall response rate and progression-free survival as potential surrogate endpoints for overall survival in immunotherapy trials.;Mushti;Clin Cancer Res,2018

5. Immune checkpoint blockade in solid organ tumours: choice, dose and predictors of response.;Navani;Br J Clin Pharmacol,2020

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Frequently asked questions on surrogate endpoints in oncology-opportunities, pitfalls, and the way forward;eClinicalMedicine;2024-09

2. Cabozantinib in combination with immune checkpoint inhibitors for renal cell carcinoma: a systematic review and meta-analysis;Frontiers in Pharmacology;2024-04-17

3. Derivative survival analyses: Analysis methods to derive survival outcomes for the remainder patient cohort without individual patient data;Cell Reports Medicine;2024-04

4. Tumor growth rate to assess therapy response to immune-based combinations for metastatic renal cell carcinoma;Expert Review of Precision Medicine and Drug Development;2024-03-18

5. Immunotherapy in renal cell carcinoma;The Lancet Oncology;2023-11